Eli Lilly: New Alzheimer’s treatment slows disease in late-stage study

Pharmaceutical giant Eli Lilly said Wednesday results from a Phase 3 study on its Alzheimer’s treatment show it slowed clinical cognitive and functional decline by 35% compared with a placebo.

Share on FacebookEmail this to someoneShare on Google+Tweet about this on TwitterPrint this pageShare on LinkedInShare on StumbleUponShare on TumblrShare on RedditFlattr the authorPin on PinterestBuffer this pageDigg this